US 11,833,146 B2
Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
Mai Miyamoto, Tsukuba (JP); and Sadaharu Kotani, Tokyo (JP)
Assigned to Eisai R&D Management Co., Ltd., Tokyo (JP)
Appl. No. 16/607,402
Filed by Eisai R&D Management Co., Ltd., Tokyo (JP)
PCT Filed May 30, 2018, PCT No. PCT/JP2018/020638
§ 371(c)(1), (2) Date Oct. 23, 2019,
PCT Pub. No. WO2018/221545, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/513,692, filed on Jun. 1, 2017.
Prior Publication US 2020/0129501 A1, Apr. 30, 2020
Int. Cl. A61K 31/4745 (2006.01); A61P 25/28 (2006.01); A61K 31/445 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 31/445 (2013.01); A61P 25/28 (2018.01)] 9 Claims
 
1. A method for treating Alzheimer's disease, comprising administering (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c] quinoline-4(5H)-one represented by formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof to a patient in need thereof.